Using Patient-Derived Glioblastoma Organoids to Predict Drug Responses and Explore New Treatments

What this Trial Is About

Researchers are investigating glioblastoma, a highly aggressive brain tumor with limited treatment options, by studying patient-derived glioblastoma organoids GBOs. These organoids are used to test how well drugs, including temozolomide and other repurposed chemotherapeutic agents, work in lab settings compared to patient responses. The study aims to see if drug responses in GBOs can predict patient outcomes like progression-free survival. The study uses an organoid-based drug sensitivity test DST to assess responses to temozolomide by measuring cell viability and determining drug sensitivity or resistance. This is a retrospective observational study where clinical outcomes from patients who have undergone standard treatment, including surgery and temozolomide-based chemoradiation therapy, are compared to the drug responses seen in their corresponding GBOs. No treatments are changed based on DST results. Participants provide tumor samples and clinical data, including genetic information and radiologic scans, which are collected prospectively. Researchers evaluate progression-free survival 12 months after surgery and overall survival after 18 months. The goal is to validate GBO-DST as a reliable preclinical model to potentially replace traditional clinical trials for glioblastoma drug testing.

Drug Response Testing and Repurposing Using Glioblastoma Organoid